ONCSQ.US OncoSec Medical Incorporated

Healthcare Biotechnology USA Stocks
0.0000 USD
Close of Nov 17, 2026
Market cap
USD 59.00
P/E
-
P/B
0.83x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jan 2023.

Is ONCSQ.US undervalued?

Graham number

The Graham number of OncoSec Medical Incorporated cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

OncoSec Medical Incorporated fundamental analysis

No fundamental analysis for OncoSec Medical Incorporated yet.

OncoSec Medical Incorporated stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About OncoSec Medical Incorporated

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacados…

Full company profile